Processa Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Processa Pharmaceuticals, Inc. (PCSA) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $356.42 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2021-11-12
- Processa Pharmaceuticals, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-09-30 was $356.42K.
- Processa Pharmaceuticals, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-06-30 was $1.51K.
- Processa Pharmaceuticals, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2020-03-31 was $2.81K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month |
|---|---|---|---|
| 2020-09-30 | $356.42K 10-Q · filed 2021-11-12 | $357.92K derived: sum of 2 quarters · filed 2021-11-12 | $360.73K derived: sum of 3 quarters · filed 2021-11-12 |
| 2020-06-30 | $1.51K 10-Q · filed 2021-11-12 | $4.31K derived: sum of 2 quarters · filed 2021-11-12 | |
| 2020-03-31 | $2.81K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |